Phacilitate’s Automation Report

An original piece of research specifically aimed at uncovering ‘The ROI from automation in cell-based therapy bioprocessing and supply chain’.

The focus will be on the impact of automation (as compared to manual processes/operations) on a range of aspects, including but not limited to: Cost of Goods, Production & delivery timescales, Footprint of equipment (relating to cost), Quality and regulatory compliance, Scalability (volumes and yields).

  1. The impact/ROI at different stages of the R&D process will be explored, from early clinical phases onwards, as well as the relative success of both outsourced and in-house approaches, and of ‘off-the-shelf’ and bespoke solutions.
  2. Expert opinion will be drawn from industry (pharma and biotech, CMOs, tool providers), academia and other global cell-based therapy experts (including regulatory experts)
  3. The scope of the report will span a range of different cell-based therapeutic platforms (including cell based immunotherapies, somatic stem cell therapies and iPSCs)
  4. Conclusions will be drawn in the form of predictions for the future impact of automation on the C> field (timescales, likely pathway(s) for future technology development) as well as recommendations for cell therapy manufacturers seeking to invest in automation today
  5. The report will be combined with the outcomes of the Automation SIG event and distilled into a Position Paper to be published in a peer-reviewed journal of standing

The report will be released in July.

Fill in the form below to find out more: